JP2015535237A5 - - Google Patents

Download PDF

Info

Publication number
JP2015535237A5
JP2015535237A5 JP2015538612A JP2015538612A JP2015535237A5 JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5 JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015538612 A JP2015538612 A JP 2015538612A JP 2015535237 A5 JP2015535237 A5 JP 2015535237A5
Authority
JP
Japan
Prior art keywords
composition
phosphate
citrate buffer
pharmaceutical composition
sucrose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015538612A
Other languages
English (en)
Japanese (ja)
Other versions
JP6431844B2 (ja
JP2015535237A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2013/059612 external-priority patent/WO2014064637A1/en
Publication of JP2015535237A publication Critical patent/JP2015535237A/ja
Publication of JP2015535237A5 publication Critical patent/JP2015535237A5/ja
Application granted granted Critical
Publication of JP6431844B2 publication Critical patent/JP6431844B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015538612A 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物 Expired - Fee Related JP6431844B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
IN1235/KOL/2012 2012-10-26
IN1236KO2012 2012-10-26
IN1236/KOL/2012 2012-10-26
IN1235KO2012 2012-10-26
PCT/IB2013/059612 WO2014064637A1 (en) 2012-10-26 2013-10-24 Stable pharmaceutical composition of tnfr:fc fusion protein

Publications (3)

Publication Number Publication Date
JP2015535237A JP2015535237A (ja) 2015-12-10
JP2015535237A5 true JP2015535237A5 (enExample) 2016-12-15
JP6431844B2 JP6431844B2 (ja) 2018-11-28

Family

ID=54208810

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015538612A Expired - Fee Related JP6431844B2 (ja) 2012-10-26 2013-10-24 Tnfr:fc融合プロテインの安定な医薬組成物

Country Status (14)

Country Link
US (2) US10058589B2 (enExample)
EP (1) EP2919801B1 (enExample)
JP (1) JP6431844B2 (enExample)
KR (1) KR102132050B1 (enExample)
CN (1) CN104936607A (enExample)
AU (1) AU2013336279B2 (enExample)
BR (1) BR112015009462A2 (enExample)
CA (1) CA2889271A1 (enExample)
ES (1) ES2806946T3 (enExample)
MX (1) MX366622B (enExample)
PL (1) PL2919801T3 (enExample)
PT (1) PT2919801T (enExample)
RU (1) RU2664691C2 (enExample)
WO (1) WO2014064637A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138181A2 (en) 2005-06-14 2006-12-28 Amgen Inc. Self-buffering protein formulations
JP2016518386A (ja) * 2013-05-02 2016-06-23 マブキシェンス エス.アー. TNFR:Fc融合ポリペプチドの代替配合物
JP6480154B2 (ja) * 2014-11-06 2019-03-06 持田製薬株式会社 エタネルセプトの凍結乾燥製剤
MX389818B (es) * 2015-08-13 2025-03-20 Landsteiner Scient S A De C V Composicion de estabilidad mejorada de etanercept.
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
ES3064802T3 (en) 2016-10-21 2026-04-29 Amgen Inc Pharmaceutical formulations and methods of making the same
US12396943B2 (en) * 2017-08-08 2025-08-26 Csl Behring Ag Hemopexin formulations
CA3042126A1 (en) 2018-05-03 2019-11-03 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of treating kawasaki disease
WO2022264097A1 (en) 2021-06-17 2022-12-22 Lupin Limited Pharmaceutical composition of anti-tumour necrosis factor (anti-tnf) agent for management of infectious diseases caused by coronaviruses
WO2025245826A1 (zh) * 2024-05-31 2025-12-04 荣昌生物制药(烟台)股份有限公司 环糊精及其衍生物作为保护剂在制备TACI-Fc融合蛋白液体药物制剂中的用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215743A (en) 1988-04-13 1993-06-01 Maninder Singh Tumor necrosis factor formulations
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
DE4239877C1 (de) * 1992-11-27 1994-03-17 Boehringer Ingelheim Int Stabilisierte Superoxid-Dismutase (SOD)-Zusammensetzung
DK1017413T4 (da) * 1997-09-23 2008-03-25 Rentschler Biotech Gmbh Flydende formulering af interferon-beta
SI1478394T1 (sl) 2002-02-27 2008-12-31 Immunex Corp STABILIZIRAN TNFR-Fc SESTAVEK Z ARGININOM
US20040033228A1 (en) * 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
BRPI0407649A (pt) 2003-02-28 2006-02-21 Ares Trading Sa formulação lìquida de proteìnas de ligação do fator de necrose tumoral, processo de preparação de formulação lìquida de proteìnas de ligação do fator de necrose tumoral e forma de apresentação de formulação
ES2310122B1 (es) * 2007-04-20 2009-10-30 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas que comprenden una ciclodextrina y una molecula biologicamente activa y sus aplicaciones.
US9296806B2 (en) * 2008-04-30 2016-03-29 Wockhardt Limited Processes for refolding of insulin
NZ595694A (en) * 2009-05-04 2013-09-27 Abbvie Biotechnology Ltd Stable high protein concentration formulations of human anti-tnf-alpha-antibodies
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
CN103458926B (zh) 2010-11-11 2016-10-26 艾伯维生物技术有限公司 改进的高浓度抗TNF α 抗体液体制剂
WO2012143418A1 (en) * 2011-04-20 2012-10-26 Sandoz Ag STABLE PHARMACEUTICAL LIQUID FORMULATIONS OF THE FUSION PROTEIN TNFR:Fc

Similar Documents

Publication Publication Date Title
RU2015119603A (ru) Стабильная фармацевтическая композиция на основе слитого белка tnfr:fc
JP2019536761A5 (enExample)
HRP20211417T1 (hr) Formulacije koje stabiliziraju i sprječavaju taloženje imunogenih pripravaka
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
JP2015527402A5 (enExample)
JP2019504086A5 (enExample)
JP2012515221A5 (enExample)
JP2018138578A5 (enExample)
JP2022166006A5 (enExample)
FI3209681T3 (fi) Peptidivariantteja käsittäviä farmaseuttisia koostumuksia ja niiden käyttömenetelmiä
JP2010529999A5 (enExample)
RU2020112952A (ru) Жидкая фармацевтическая композиция
JP2013521296A5 (enExample)
JP2013543505A5 (enExample)
JP2011502968A5 (enExample)
EA201891154A1 (ru) Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
EA201200096A1 (ru) Фармацевтическая композиция ингибитора протеазы вируса гепатита c
RU2015132431A (ru) Составы, содержащие антитела
HRP20250382T1 (hr) Farmaceutski pripravak koji sadrži karbetocin
RU2010141542A (ru) Низковязкие высокофлокулированные суспензии триамцинолона ацетонида для интравитреальных инъекций
RU2017101667A (ru) Фармацевтические композиции
JP2015521593A5 (enExample)
JP2016539921A5 (enExample)
AR082024A1 (es) Formulacion de anticuerpo contra ox40l humano
JP2017516848A5 (enExample)